Clinical Trial of Mica

Prior treatment

• The interval between other subunit vaccines and inactivated vaccines was less than 7 days, and the interval between attenuated live vaccines was less than 14 days before enrollment;

Other illness

• Patients with a history of severe drug allergy, vaccine allergy, allergic constitution or known allergy to experimental drugs;
• Patients currently suffering from tuberculosis;
• Acute fever diseases, infectious diseases (including but not limited to measles, whooping cough, influenza, pneumonia, etc.), diabetes mellitus with complications, acute or progressive liver or kidney disease, acute conjunctivitis of the eye, acute otitis media, severe heart disease, severe hypertension, myocardial damage, significant vascular sclerosis, patients with endocarditis, patients with malignant tumors, etc.;
• Patients with a history of convulsions, epilepsy, encephalopathy, and neurological symptoms or signs upon examination;
• Chest imaging examination showed active tuberculosis;
• Patients with abnormal thyroid palpation or a history of thyroid/parathyroid disease;

Other

• Patients with extreme weakness and severe anemia;
• Women who are pregnant or breastfeeding, who test positive for pregnancy, or who cannot guarantee contraception during the study period of this clinical trial;
• Any circumstances which the investigator considers likely to influence the evaluation of the test.

• Age 15 and above (≥15 years old), gender unlimited;
• I (and my guardian) agree to participate in this study and sign the informed consent, willing and able to comply with the requirements of the clinical study protocol;
• Patients with normal body temperature (axillary temperature \< 37.3℃);
• The mean diameter of the skin test of recombinant mycobacterium tuberculosis fusion protein (EC) is not less than 5mm, or there are blisters, necrosis, lymphangiitis.